Investing in Medical Devices, The News Isn't All Bad
The stock market slump for small cap medical device firms has meant problems for public investors. As disappointing sales and earnings have pushed down stock prices, those who bought in at the IPO have nearly all lost money. Not so for private investors, who still see a healthy return from the last round of private financing. Some believe the current slump is only temporary. If it isn't, expect a smaller gap between last private round and IPO valuations.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.